“Global spending on the fight to tackle malaria is peaking, despite an increasing contribution from the UK. The risk is that the progress made so far will stall and that there will be a rapid resurgence of the disease. The Department’s bilateral programmes use proven interventions, such as providing bed nets, and funding the introduction of rapid diagnostic tests and the distribution of drugs. But sustained improvement will crucially depend on changing the attitudes and behaviour of the populations at risk. It is important that the Department influence the governments of countries receiving malaria aid so that their efforts to tackle the disease match its own rising spending.” - Amyas Morse, head of the National Audit Office, 3 July 2013
The World Malaria Report 2012 summarizes information received from 104 malaria-endemic countries and other sources, and updates the analyses presented in the 2011 report. It highlights the progress made towards the global malaria targets set for 2015, and describes current challenges for global malaria control and elimination.
The goal of AMFm is to improve access to artemisinin-based combination therapies (ACTs), the most effective anti-malaria treatment. The AMFm pilot phase was launched in April 2009 and began operations in July 2010. It set out to increase availability, particularly through private outlets where most people seek their treatments, and drive down the price of ACTs through a factory-gate global subsidy of ACTs combined with country-level measures to support its implementation.